Narcolepsy - Pipeline Review, H2 2018

Publisher Name :
Date: 09-Oct-2018
No. of pages: 88
Inquire Before Buying

Narcolepsy - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2018, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 4, 4, 5, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Narcolepsy - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Narcolepsy - Overview
Narcolepsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Narcolepsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Narcolepsy - Companies Involved in Therapeutics Development
Avadel Pharmaceuticals Plc
Bioprojet SCR
Evotec AG
F. Hoffmann-La Roche Ltd
H.A.C. Pharma
Heptares Therapeutics Ltd
Jazz Pharmaceuticals Plc
Ono Pharmaceutical Co Ltd
OptiNose US Inc
SK Biopharmaceuticals Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Theranexus SAS
Narcolepsy - Drug Profiles
(flecainide acetate + modafinil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-258 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-386 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentylenetetrazol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pitolisant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium oxybate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium oxybate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solriamfetol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVNG-3031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XW-10172 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XW-10282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Narcolepsy - Dormant Projects
Narcolepsy - Discontinued Products
Narcolepsy - Product Development Milestones
Featured News & Press Releases
Sep 10, 2018: XW Labs appoints clinical development veteran Dr. Daniel Canafax as Chief Medical Officer
Sep 05, 2018: Harmony Biosciences to present data on its investigational product, Pitolisant, at upcoming International Narcolepsy Symposium
Jun 27, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy
Jun 03, 2018: Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea
Jun 01, 2018: Suven Life Sciences participating at Sleep 2018 at Baltimore, MD. USA
May 31, 2018: Harmony Biosciences to Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting
May 22, 2018: Bioprojet: Pitolisant Progresses Towards the U.S. Market
May 21, 2018: Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant
May 10, 2018: Jazz Pharmaceuticals to Present Data on Sodium Oxybate at SLEEP 2018 Annual Meeting
May 10, 2018: Jazz Pharmaceuticals to Present Data on Solriamfetol at SLEEP 2018 Annual Meeting
May 01, 2018: Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Mar 22, 2018: AOP Orphan will distribute Wakix (pitolisant) from Bioprojet Pharma in Austria, Nordic countries and Central Eastern Europe
Mar 12, 2018: XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment
Mar 02, 2018: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Narcolepsy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H2 2018
Narcolepsy - Pipeline by Bioprojet SCR, H2 2018
Narcolepsy - Pipeline by Evotec AG, H2 2018
Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Narcolepsy - Pipeline by H.A.C. Pharma, H2 2018
Narcolepsy - Pipeline by Heptares Therapeutics Ltd, H2 2018
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H2 2018
Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
Narcolepsy - Pipeline by OptiNose US Inc, H2 2018
Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018
Narcolepsy - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018
Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Narcolepsy - Pipeline by Theranexus SAS, H2 2018
Narcolepsy - Dormant Projects, H2 2018
Narcolepsy - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Narcolepsy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Anesthetic Effect - Pipeline Review, H2 2018
    Published: 30-Oct-2018        Price: US 2000 Onwards        Pages: 82
    Anesthetic Effect - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H2 2018, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape. Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of ad......
  • Schizophrenia - Pipeline Review, H2 2018
    Published: 30-Oct-2018        Price: US 2000 Onwards        Pages: 321
    Schizophrenia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H2 2018, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape. Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and dis......
  • Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018
    Published: 30-Oct-2018        Price: US 2000 Onwards        Pages: 551
    Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape. Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathop......
  • Insomnia - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 116
    Insomnia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H2 2018, provides an overview of the Insomnia (Central Nervous System) pipeline landscape. Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distre......
  • Spinal Cord Injury - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 199
    Spinal Cord Injury - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2018, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape. Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually cau......
  • Guillain-Barre Syndrome - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 51
    Guillain-Barre Syndrome - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2018, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape. Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include ......
  • Low Back Pain - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 113
    Low Back Pain - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H2 2018, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape. Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms inc......
  • Binge Eating Disorder - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 50
    Binge Eating Disorder - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2018, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape. Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family hist......
  • Rett Syndrome - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 122
    Rett Syndrome - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome - Pipeline Review, H2 2018, provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape. Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Sta......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs